CAD-1005 (formerly VLX-1005)

October 7, 2026: Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) said its board has launched a formal strategic review to evaluate partnerships and other transactions across its portfolio, citing recent FDA alignment on the Phase 3 development pathway for CAD-1005 and interest from potential strategic partners. The process may include licensing or sales of assets, development/commercialization partnerships, portfolio transactions, business combinations, or other strategic deals; Tungsten Advisors was engaged as exclusive financial advisor.

Programs cited:

• CAD-1005: first-in-class 12-LOX inhibitor for heparin-induced thrombocytopenia (HIT). Cadrenal said it recently aligned with FDA on a Phase 3 registration-study pathway. The program has FDA Orphan Drug and Fast Track designations and EMA orphan drug status.
• Tecarfarin: Phase 3-ready oral vitamin K antagonist for chronic anticoagulation, including end-stage kidney disease, atrial fibrillation, and left ventricular assist device patients; has FDA Orphan Drug and Fast Track designations for certain indications.
• Frunexian: investigational parenteral Factor XIa inhibitor for acute and critical care settings, including major cardiac surgery.
• CAD-2000: preclinical oral next-generation 12-LOX inhibitor for immunology/inflammation, including obesity-driven inflammation, MASH, and chronic cardiorenal diseases.

The company said there is no assurance the strategic process will result in a transaction.